Adaptive Biotechnologies (ADPT) EBIT Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed EBIT Margin across 9 years of filings, most recently posting 22.04% for Q2 2026.

• In Q2 2026, EBIT Margin rose 2048.0% year-over-year to 22.04%; the TTM figure through Jun 2026 stood at 12.16% (up 4686.0% YoY), while the FY2025 annual figure was 20.62%, up 7021.0% from the prior year.
• EBIT Margin came in at 22.04% for Q2 2026 at Adaptive Biotechnologies, up from 27.1% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 10.95% in Q3 2025 to a low of 163.3% in Q1 2022.
• Average EBIT Margin over 5 years is 83.96%, with a median of 83.14% recorded in 2022.
• Year-over-year, EBIT Margin surged 9140 bps in 2022 and sank 8423 bps in 2023.
• Over 5 years, EBIT Margin stood at 70.99% in 2022, then slumped by 119 bps to 155.22% in 2023, then soared by 54 bps to 71.3% in 2024, then jumped by 75 bps to 17.82% in 2025, then fell by 24 bps to 22.04% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 22.04% in Q2 2026, 27.1% in Q1 2026, and 17.82% in Q4 2025.